Background: The prognostic score of the International Germ-Cell Cancer Collaborative Group (IGCCCG) in metastatic germ-cell cancers (mGCC) relies on treatments delivered before 1990. It is unclear, if this score is still relevant to contemporary cohorts of patients who receive modern-type chemotherapy and supportive care.
Introduction
In 2017, an estimated number of 8850 new cases of germ-cell cancers (GCC) will be diagnosed in the United States [1] . Although GCC show a high sensitivity to cisplatin-based chemotherapy (CDCT), 10%-15% of patients fail first-line treatment and 3%-5% of all GCC patients will eventually die of their disease [2] . In 1997, the International Germ-Cell Cancer Cooperative Group (IGCCCG) published a prognostic classification for metastatic GCC (mGCC) to direct and optimize treatments [3] . The resulting IGCCCG score has become the reference for treatment decisions in mGCC ever since. However, as the IGCCCG score relies on treatments delivered between 1975 and 1990 and as diagnostic and therapeutic standards as well as supportive care have improved substantially since that time, this study aimed to assess the performance of the IGCCCG score in a contemporary patient cohort.
Patients and methods
All patients who underwent first-line chemotherapy at the University Hospital Zurich (USZ) between 1991 and 2016 for mGCC were identified. Inclusion criteria for the analysis were modern type combination chemotherapy consisting of at least three or more cycles of cisplatin and etoposide (EP) with or without bleomycin or ifosfamide. The year 1991 war chosen as a starting point for the analysis as the combination of cisplatin, etoposide and bleomycin (BEP) was routinely used at the USZ since the publication of Williams et al. in 1987 demonstrating superiority of BEP over the vinblastine containing combination [4] . Bleomycin was either omitted or replaced by ifosfamide in the event of contraindications to this drug. Also high-dose chemotherapy using carboplatin and etoposide was introduced in 1990 as salvage treatment at the USZ after the initial publication of Nichols et al. [5] .
All patients with residual tumors after chemotherapy were routinely scheduled for post-chemotherapy surgery. Patients with relapse or progression after first-line treatment were scheduled for salvage treatment based individually on relapse presentation and risk factors at the time.
We extracted clinical characteristics such as age at diagnosis, location of primary tumor, histology, location of metastases, levels of alphafetoprotein (AFP), human chorionic gonadotropin (HCG) and lactate dehydrogenase (LDH) from electronic medical charts and calculated the individual IGCCCG score for each patient [3] . The study was approved by the local ethics committee (STV KEK-ZH 25-2008).
The end points of the study were the progression-free survival (PFS) and overall survival (OS) probabilities at 5 years. PFS started with the initiation of chemotherapy and ended with progression or death, whichever occurred first. OS started with the initiation of chemotherapy and ended with the death of a patient. Survival status was identified from medical charts or death certificates. Patients without an event were censored at the date of last follow-up.
PFS and OS were calculated according to the Kaplan-Meier method and compared using the log-rank test. Survival probabilities are reported together with the corresponding standard error (SE) and 95% confidence intervals (95% CI). Statistical analyses were carried out using the STATA software Version 10.0 (StataCorp LLC, College Station, TX). Continuous non-normally distributed variables are presented as median and interquartile ranges (IQR) and categorical variables are presented as percentages. Probabilities P <0.05 were considered statistically significant. All statistical tests were two-sided.
Results

Patients' characteristics
The final study cohort consisted of 204 patients at a median age of 32 years (IQR 26-39 years) and median follow-up time of 4, 2 years (IQR 1, 9-7, 8 years) ( The contemporary USZ cohort was comparable to the historical IGCCCG cohort. Imbalances were found for the number of seminoma patients and patients with mediastinal primary tumors, which were more frequent in the contemporary cohort. Patients with brain metastases were more frequent in the historical cohort.
Despite these imbalances, the historical IGCCCG and the contemporary USZ cohort showed similar distributions in respect to the IGCCCG risk groups, with 60% versus 62% low risk patients, 26% versus 19% intermediate-risk patients and 14% versus 19% poor-risk patients, respectively. Compared with the historical IGCCCG cohort less intermediate-risk and slightly more goodand poor-risk patients were observed ( Table 2 ).
In the contemporary USZ cohort treatment consisted of three or four cycles of BEP in 184/204 (90%) patients, cisplatin and etoposide in 6/204 (3%) patients, cisplatin, etoposide and ifosfamide in 8/204 (4%) patients and other cisplatin-and etoposide-based regimens in 6/204 (3%) patients. Overall 57/204 (28%) relapses occurred, 9/52 (17%) among patients with pure seminoma and 48/ 143 (34%) among patients with non-seminoma or mixed histologies. Salvage treatment in relapsed patients consisted of surgery alone in 12/57 (21%) patients with teratoma, conventionaldose CDCT in 13/57 (23%) patients, sequential high-dose chemotherapy (HDCT) with carboplatin and etoposide in 23/57 (40%) patients, and CDCT followed by HDCT in 7/57 (12%) patients. Two patients died before any salvage treatment could be given (Table 3) . Residual tumor resections after completion of salvage chemotherapy were carried out in 17/43 (40%) patients. OS in relapsing when compared with non-relapsing patients is shown as supplementary Figure S1 , available at Annals of Oncology online.
Survival
The published IGCCCG score correctly divided the contemporary USZ cohort into three distinct and significantly different groups for PFS with probabilities of 83% (SE: 3.6%; 95% CI: 75% to 89%), 69% (SE: 8%; 95% CI: 50% to 82%) and 30% (SE: 10%; 95% CI: 13% to 50%) at 5 years (P < 0.001) (Figure 1 ). These probabilities are very similar to the predicted ones according to the published IGCCCG score ( Table 2 ). The OS probabilities in the contemporary USZ cohort were 95% (SE: 2.1%; 95% CI: 89% to 98%), 91% (SE: 4.8%; 95% CI: 76% to 97%), and 65% (SE: 8.9%; 95% CI: 44% to 79%) for good-, intermediate-and poor-risk patients, respectively. Compared with the OS probabilities predicted by the published IGCCCG score, this represents a marked improvement in OS among intermediate-and poor-risk patients, and only a slight improvement among good-risk patients in the contemporary USZ cohort (Figure 2) . In respect to OS, the IGCCCG score did no longer predict separate probabilities for the groups of good and intermediate-risk patients (P ¼ 0.62). Only OS for poor-risk patients was correctly predicted by the historical IGCCCG score with a significantly inferior OS probability compared with good and intermediate-risk patients (P < 0.001).
Discussion
Substantial improvements in diagnostic and therapeutic standards have occurred since the introduction of cisplatin into the treatment of mGCC. Our present retrospective analysis, however, demonstrated that the observed PFS probabilities for mGCC after first-line chemotherapy did not differ compared with the ones predicted by the IGCCCG score despite these improvements. Although, the IGCCCG score, which was developed based on treatments delivered between 1975 and 1990, still correctly divided our more contemporary USZ cohort treated between 1991 and 2016 into three risk groups based on their PFS, the PFS probabilities within these three risk groups have not improved. Possibly the efficacy of cisplatin-based treatment had already been high in the IGCCCG cohort so that further improvements might have been too small to be detected, the rate of treatmentrelated deaths might have been too low and the contemporary patient cohort studied too small to detect any improvements in first-line treatment that may have occurred since 1990. Treatment intensification using dose-dense or upfront high-dose chemotherapy in poor-risk patients, in whom most of the benefit of treatments intensification can be expected, had not been used during the study period at our center [6] .
In contrast, the observed OS probabilities have markedly improved particularly among intermediate-and poor-risk patients in the contemporary USZ cohort when compared with the OS probabilities predicted by the IGCCCG score. The OS probabilities at 5 years increased from 91% as predicted to 95% observed among good-risk patients, from 79% as predicted to 91% observed among intermediate-risk patients and from 48% as predicted to 65% observed among poor-risk patients. With these improvements the observed OS probabilities among the IGCCCG risk groups were no longer different between the goodand intermediate-risk patients (P ¼ 0.62), but still significantly Figure S1 , available at Annals of Oncology online. Pat., number of patients; CDCT, conventional-dose chemotherapy; HDCT, high-dose chemotherapy; remission, complete remission or partial remission with negative serum tumor markers. different between those two risk groups and poor-risk patients (P < 0.001). The comparison of the probabilities for PFS and OS as predicted by the published IGCCCG score and the ones observed in our contemporary USZ cohort produced three important findings. First, the IGCCCG score is no longer prognostic for OS among intermediate-risk patients. In our contemporary USZ cohort the good-and intermediate-risk groups showed similar OS probabilities indicating that the IGCCCG score no longer separates these two risk groups sufficiently well. Modifications of the published IGCCCG score with better discrimination of intermediate-and poor-risk patients have been suggested in an attempt to avoid overtreatment as well as undertreatment of mGCC patients [7] .
Second, since early 1970, improvements in diagnosis and treatment of GCC have mainly consisted in better staging using computed tomography and magnetic resonance tomography scans as well as improved supportive care. Apart from etoposide with superior activity compared with vinblastine, no new active agent has been introduced into the standard first-line treatment of mGCC [4] . Therefore the current recommendation for firstline treatment remains three to four cycles BEP or EP depending on the IGCCCG risk group [8] [9] [10] [11] . Very recently only, intensive dose-dense combination chemotherapy has demonstrated superior PFS, but not OS in a cohort of poor-risk patients with an unfavorable marker decline after the first-cycle of BEP [6] . While current improvements in supportive care have certainly improved tolerability of cisplatin-based combination treatment, our data demonstrate comparable PFS probabilities between the PFS as predicted by the IGCCCG score and the observed PFS in our contemporary USZ cohort. This confirms the limited Figure 1 . Progression-free survival probabilities in the contemporary cohort of the University Hospital Zurich (n ¼ 204). improvements in efficacy of conventional-dose first-line treatments of mGCC since early 1970. Third, there are several explanations for an improved OS in mGCC patients in our more contemporary cohort. Better diagnostic tools and structured follow-up schedules might have resulted in the earlier diagnosis of relapses occurring in patients with less advanced disease. Improvements in supportive care with better management of infectious complications, less treatment delays due to the availability of hematopoietic growth factors as well as more experience in the management of organ toxicities might have had a greater impact after the more toxic salvage when compared with the less toxic first-line treatment. However, the biggest contribution to the improvements in OS comes from better salvage strategies that have changed substantially since 1990. Conventional-dose first salvage chemotherapy has integrated new drugs with single agent activity in cisplatinrefractory patients such as ifosfamide and paclitaxel [12, 13] . High-dose chemotherapy is being used more regularly as first or subsequent salvage treatment [14, 15] . Salvage surgery is being applied more aggressively [16] . And finally effective third-line treatment options have become available integrating gemcitabine and oxaliplatin with reported long-term survivors even in prognostically unfavorable groups of patients [17] . With the lack of prospective randomized trials, however, it will be impossible to dissect the individual contribution of each of these interventions, which are all reflected in our contemporary patient cohort studied.
The present analysis is limited by its retrospective design, single center approach and small sample size. Moreover, we were only able to compare the survival probabilities predicted by the IGCCCG score to the ones actually observed at our center. As we did not have access to the original IGCCCG data, we cannot make, and did not intend to perform direct comparisons between the initial IGCCCG cohort and our contemporary patient cohort. Patients referred to a tertiary cancer center will always be selected and will not be representative for the population of all mGCC patients. An analysis of a larger, less selected and multicenter cohort and a comparison to the original IGCCCG data might result in different findings. However, almost identical results have been presented from Germany at the meeting of the European Society of Medical Oncology among patients treated within a community service [18] . Finally, unknown confounders other than the ones mentioned above may have impacted on the better OS probabilities observed in the contemporary USZ cohort. However, despite these shortcomings the present analysis is hypothesis generating and provides the rationale for an ongoing international multi-center effort to study the results of modern type chemotherapy in a much larger and less selected patient cohort of mGCC.
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